Table 2.
Neurotoxicity in selected non-CD I9-directed chimeric antigen receptor (CAR) T cells for hematologic malignancies
| References (first author, year) | NCI | N | Age group | CAR target | CAR construct | Disease | CRR (%) | sNT (%) | NT (%) | CRS (%) | sCRS (%) | toci (%) | steroids (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fry. 2018 [28] | NCT02315612 | 21 | Peds. adult | CD22 | 4-IBB | ALL (majority CD19 CAR pretreated) | 57a 43b |
0 | 25 | 76 | 0 | 0 | 0 |
| Ramos, 2017 [27] | NCT01316146 | 9 | Adult | CD30 | 28z | HL, ALCL | 33 | 0 | 0 | 0 | 0 | n/a | n/a |
| Wang. 2017 [29] | NCT02259556 | 18 | Peds, adult | CD30 | 4-IBB | HL | 0 | 0 | 0 | 0 | 0 | n/a | n/a |
| Ali. 2016 [30] | NCT02215967 | 12 | Adult | BCMA | 28z | MM | 8 | 8 | 25 | 50 | 25 | 33 | 0 |
| Ritchie. 2013 [3 1] | CTX 08-0002 | 4 | Adult | LeY | 28z | AML | 25 | 0 | 0 | 25 | 0 | 0 | 0 |
4–1BB 4–1BB co-stimulatory domain, 28z CD28 co-stimulatory domain. ALCL anaplastic large cell lymphoma. ALL acute lymphoblastic leukemia. AML acute myelogenous leukemia, BCMA B-cell maturation antigen. CRR complete remission rate. CRS cytokine release syndrome. HL Hodgkin’s lymphoma, MM multiple myeloma. n/a not available. NCI’ national clinical trial. NT neurotoxicity. peds pediatrics, sCRS severe CRS, sNT severe neurotoxicity (Common Terminology Criteria for Adverse Events grade 3 or higher), steroids corticosteroids. foci tocilizumab
a
Morphologic remission
b
Minimal residual disease-negative remission